Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Smilow Cancer Center/yale-New Haven Hospital
New Haven, Connecticut, United States
- Yale University
New Haven, Connecticut, United States
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Northwestern University
Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Uc Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, United States
- University of Chicago Medicine-Orland Park
Orland Park, Illinois, United States
- University of Kansas Clinical Research Center
Fairway, Kansas, United States
- University of Kansas Cancer Center
Kansas City, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
- Nebraska Medicine-Village Pointe
Omaha, Nebraska, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Dartmouth Hitchcock Medical Center/dartmouth Cancer Center
Lebanon, New Hampshire, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Ut Southwestern/simmons Cancer Center-Dallas
Dallas, Texas, United States
- Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Jun 2017
- Primary completion
- 4 Nov 2022
- Completion
- 12 Feb 2025
- Last update posted
- 25 Mar 2025
- Registered enrollment
- 28
- Registry id
- NCT02936752
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.